A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
复制标题
DOI：
10.1002/jmv.27811
复制
发表时间：
2022-08
影响因子：
12.7
通讯作者：
Zhang, Zheng
中科院分区：
文献类型：
--
作者：
Zhou, Bing;Song, Shuo;Guo, Huimin;Zhou, Xinrong;Fan, Qing;Liu, Weilong;Cheng, Lin;Ge, Xiangyang;Ju, Bin;Zhang, Zheng
SARS-CoV-2疫苗已被广泛用于在人群中建立免疫屏障以抵御COVID-19大流行。然而，一种新出现的Omicron变体，包括BA.1、BA.1.1、BA.2和BA.3亚系，在很大程度上逃脱了现有中和抗体（nAb）的中和，甚至是三剂疫苗引起的中和抗体。在这里，我们使用Omicron BA.1 RBD作为第四剂疫苗，以诱导有效的Omicron特异性nAb，并评估针对SARS-CoV-2变体的广泛中和活性。基于BA.1的疫苗确实倾向于诱导与BA.2亚系实质性交叉反应的毒株特异性抗体应答，但当其用于WT和其他变体疫苗的序贯免疫时，触发了对SARS-CoV-2变体的广泛中和。这些结果表明，Omicron RBD疫苗的加强剂可能是提高广泛nAb应答的合理策略。
The SARS‐CoV‐2 vaccines have been widely used to build an immunologic barrier in the population against the COVID‐19 pandemic. However, a newly emerging Omicron variant, including BA.1, BA.1.1, BA.2, and BA.3 sublineages, largely escaped the neutralization of existing neutralizing antibodies (nAbs), even those elicited by three doses of vaccines. Here, we used the Omicron BA.1 RBD as a fourth dose of vaccine to induce potent Omicron‐specific nAbs and evaluated the broadly neutralizing activities against SARS‐CoV‐2 variants. The BA.1‐based vaccine was indeed prone to induce a strain‐specific antibody response substantially cross‐reactive with BA.2 sublineage, and yet triggered broad neutralization against SARS‐CoV‐2 variants when it was used in the sequential immunization with WT and other variant vaccines. These results demonstrated that the booster of Omicron RBD vaccine could be a rational strategy to enhance the broadly nAb response.
登录
查看更多内容
影响因子：
13.2
作者：
Wang X;Zhao X;Song J;Wu J;Zhu Y;Li M;Cui Y;Chen Y;Yang L;Liu J;Zhu H;Jiang S;Wang P
通讯作者：
Wang P
DOI：
10.1056/nejmoa2201570
发表时间：
2022-05-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
通讯作者：
--
影响因子：
30.3
作者：
Ai, Jingwen;Wang, Xun;He, Xinyi;Zhao, Xiaoyu;Zhang, Yi;Jiang, Yuchao;Li, Minghui;Cui, Yuchen;Chen, Yanjia;Qiao, Rui;Li, Lin;Yang, Lulu;Li, Yi;Hu, Zixin;Zhang, Wenhong;Wang, Pengfei
通讯作者：
Wang, Pengfei
DOI：
10.1056/nejmoa2110345
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Thomas SJ;Moreira ED Jr;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Polack FP;Zerbini C;Bailey R;Swanson KA;Xu X;Roychoudhury S;Koury K;Bouguermouh S;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Yang Q;Liberator P;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Gruber WC;Jansen KU;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
64.8
作者：
Pozzetto, Bruno;Legros, Vincent;Trouillet-Assant, Sophie
通讯作者：
Trouillet-Assant, Sophie